The Revenue Rises
  • Politics
  • Stocks
  • Business
  • Economy
Trending Now
S&P 500 Earnings for 2025 Q1 — Still...
Money’s Not Leaving the Market — It’s Rotating!
From Oversold to Opportunity: Small Caps on the...
Tariffs and weaker beer demand are weighing on...
Essence Fest leads a summer of events for...
Pullbacks & Reversals: Stocks Setting Up for Big...
S&P 500 Earnings for 2025 Q1 — Still...
Market Signals Align – Is a Bigger Move...
MACD Crossovers: Why Most Traders Get It Wrong
Should You Buy Roblox Stock Now? Key Levels...

The Revenue Rises

  • Politics
  • Stocks
  • Business
  • Economy
Stocks

DexCom Stock Rises From the Ashes: A Breakout You Can’t Ignore

by admin January 18, 2025
January 18, 2025
DexCom Stock Rises From the Ashes: A Breakout You Can’t Ignore

As advancements in medical technology continue to shape the healthcare landscape, DexCom, Inc. (DXCM) stands out with its innovative continuous glucose monitoring solutions. Recent price action suggests that DXCM’s stock price has triggered a potentially new bullish run. In this article, I will examine the technical and fundamental factors behind this positive outlook and outline a risk-defined options strategy — all identified via the OptionsPlay Strategy Center within StockCharts.com.

After consolidating between $75 and $80 over the past two months, DXCM’s stock price recently broke out of this trading range with impressive relative strength.

  • Range Breakout. The stock’s breakout above $80 marks a decisive breakout from its consolidation zone.
  • Outperformance. The breakout has been coupled with outperformance to the S&P 500.
  • Upside Target. Given the breakout, there is potential for DXCM’s stock price to fill the gap up to the $107.50 level.

FIGURE 1. DAILY CHART OF DXCM STOCK. The stock price traded between $75 and $80 since the end of November. DXCM recently broke out of its consolidation zone and traded above $80.Chart source: StockCharts.com. For educational purposes.

Beyond the charts, DXCM’s fundamentals support its premium valuation:

  • Premium but justified. While trading at 39x forward earnings, DXCM’s superior growth expectations and higher net margins than peers suggest that this valuation is justified.
  • Potential for substantial upside. Robust demand in the continuous glucose monitoring market and DexCom’s leadership position the company to capitalize on ongoing trends. The combination of strong growth prospects and healthy margins provides the potential for further appreciation.

Options Strategy

Based on this bullish thesis, the OptionsPlay Strategy Center highlights a bull put spread.

  • Sell: February 28, 2025, $84 Put at $5.40
  • Buy: February 28, 2025, $77 Put at $2.42
  • Net Credit: $2.98 per share (or $298 total per contract, since each contract represents 100 shares)

FIGURE 2. DXCM BULL PUT SPREAD RISK CURVE.

Trade Details

  • Maximum Potential Reward: $298
  • Maximum Potential Risk: $402
  • Breakeven Point: $81.02
  • Probability of Profit: 58.58%

This strategy benefits from time decay and a bullish outlook, providing limited risk and a defined reward. At expiration, profits are earned if DXCM’s stock price remains above the breakeven level.

Unlock Real-Time Trade Ideas

This bullish trade in DXCM was identified using the OptionsPlay Strategy Center within StockCharts.com. The platform’s Bullish Outperform scan (see below) automatically flagged DXCM as the best candidate for selling a Bull Put Spread out of the many stocks currently outperforming the market, then structured the optimal options trade — helping you save hours of research.

FIGURE 3. BULLISH OUTPERFORMANCE SCAN. DXCM was identified as a candidate for a bull put spread.


By subscribing to the OptionsPlay Strategy Center, you gain access to:

  •  Automated Market Scans. Quickly discover high-probability trading opportunities based on technical and fundamental signals.
  • Optimal Trade Structuring. Receive tailored, real-time options strategies for your market outlook and risk tolerance.
  • Time-Saving Insights. Make informed decisions faster, avoiding the time-consuming process of manual analysis.

Don’t miss out on your next high-conviction idea. Subscribe to the OptionsPlay Strategy Center today and unlock a streamlined approach to uncovering the best options trades—all within seconds, every single day. Let OptionsPlay be your strategic ally in navigating the markets efficiently and effectively.

previous post
American Express to pay $230 million to settle DOJ fraud probe, deceptive marketing claim
next post
S&P 500 climbed 0.3%, and Nasdaq-100 futures jumped 0.7%

Related Posts

Why the S&P 500 Won’t Break 6000 (Yet)

October 27, 2024

The Sign of Strong Charts Getting Stronger

November 15, 2024

Three Signs of the Bear and What May...

February 20, 2025

What Would a Top in Semiconductors Mean for...

September 3, 2024

These S&P 500 Stocks Are Poised To Outperform!

November 3, 2024

This Precious Metal is On the Verge of...

March 27, 2025

AI Stocks Ignite Again—Where Smart Money is Heading...

June 24, 2025

Here’s My Most-Likely Scenario for QQQ

September 14, 2024

American Association of Individual Investors (AAII) Hitting Bearish...

March 8, 2025

The SCTR Report: Learn How to Scan and...

October 31, 2024

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • S&P 500 Earnings for 2025 Q1 — Still Overvalued
    • Money’s Not Leaving the Market — It’s Rotating!
    • From Oversold to Opportunity: Small Caps on the Move
    • Tariffs and weaker beer demand are weighing on Modelo owner Constellation Brands
    • Essence Fest leads a summer of events for Black entrepreneurs galvanized by economic uncertainty

    Popular Posts

    • 1

      Polls show some good early signs for Kamala Harris

      July 26, 2024
    • 2

      Solana and Cardano: Solana is waiting for a new impulse

      July 18, 2024
    • 3

      The presidential race shifts — modestly, so far — toward Harris

      August 6, 2024
    • 4

      Donald Trump’s imaginary and frightening world

      September 23, 2024
    • 5

      A Harris-Trump race would pit ex-prosecutor vs. recently convicted felon

      July 22, 2024

    Categories

    • Business (729)
    • Economy (975)
    • Politics (873)
    • Stocks (867)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: therevenuerises.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 The Revenue Rises. All Rights Reserved.